Obinutuzumab (Genentech) success in Phase III trial for CLL
Genentech has announced positive results from Stage 1 of CLL11, a Phase III randomized study to investigate the efficacy and safety profile of the investigational medicine obinutuzumab (GA101) plus chlorambucil chemotherapy compared with chlorambucil alone in people with previously untreated Chronic Lymphocytic Leukemia (CLL). An improvement in progression-free survival (PFS) was achieved as GA101 plus chlorambucil significantly reduced the risk of disease worsening or death compared to chlorambucil alone.
GA101 has been specifically designed as the first glycoengineered, type 2 anti-CD20 monoclonal antibody in development for B-cell malignancies. In pre-clinical development, GA101 has shown evidence of increased direct cell killing and antibody-dependent cellular cytotoxicity (ADCC). As a result, GA101�s clinical development program is designed to assess whether or not it is superior to Rituxan (rituximab) in CLL and Non-Hodgkin�s Lymphoma (NHL
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.